Trump aid spending freeze halts leading malaria vaccine programme

Global collaboration with US researchers likely to be set back by years, including on spread of drug-resistant HIV

A flagship programme to create malaria vaccines has been halted by the Trump administration, in just one example of a rippling disruption to health research around the globe since the new US president took power.

The USAid Malaria Vaccine Development Program (MVDP) - which works to prevent child deaths by creating more effective second-generation vaccines - funds research by teams collaborating across institutes, including the US university Johns Hopkins and the UK's University of Oxford.